Cidara Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cidara Therapeutics Inc (CDTX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cidara Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 65M vs 153,742M combined for tracked competitors (0.0% combined share).
- Peer differentiation: Revenue per employee of $0.94M compares with $0.86M for the peer group (1.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Cidara Therapeutics Inc vs. its Competitors, Q3 2025
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Cidara Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Cidara Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Cidara Therapeutics Inc's competitor groups requires a Commercial License.
Cidara Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cidara Therapeutics Inc | - | - | - | No |
| Competitors combined (7) | ||||
| High-Confidence Competitors (4) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CDTX Stock Performance relative to its Competitors
CDTX Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Arcus Biosciences Inc | 282.9% | Outperformed |
| 2 | Atea Pharmaceuticals Inc | 282.9% | Outperformed |
| 3 | Gilead Sciences Inc | 282.9% | Outperformed |
| 4 | Pfizer Inc | 282.9% | Outperformed |
| 5 | Astrazeneca Plc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cidara Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Cidara Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Cidara Therapeutics Inc | 5,951.22 | 65.06 |
| Astrazeneca Plc | 259,526.30 | 58,739.00 |
| Gilead Sciences Inc | 189,197.03 | 30,457.00 |
| Pfizer Inc | 163,675.28 | 63,696.00 |
| Arcus Biosciences Inc | 3,153.76 | 117.00 |
| Amphastar Pharmaceuticals Inc | 1,211.32 | 730.02 |
| SUBTOTAL | 623,185.80 | 153,807.01 |
Sign in to see all competitors of Cidara Therapeutics Inc .
Sources: Cidara Therapeutics Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cidara Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cidara Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Pfizer, Inc. | Named by the company | 85% |
| Scynexis, Inc. | Named by the company | 85% |
| Glenmark Generics Inc. | Named by the company | 85% |
| Astellas Pharma US, Inc. | Named by the company | 85% |
| Merck & Co. | Named by the company | 85% |
| Baxter Healthcare Corporation | Named by the company | 85% |
| Mylan Inc. | Named by the company | 85% |
| Astrazeneca Plc | Named by the company | 85% |
| Arcus Biosciences Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Cidara Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Cidara Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Arcus Biosciences Inc | Reportable 100.00 % |
| Amphastar Pharmaceuticals Inc | Pharmaceutical products segment 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Cidara Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cidara Therapeutics Inc | 5,951 | 942,841 | -2,150,957 |
| Astrazeneca Plc | 259,526 | 706,847 | 123,141 |
| Gilead Sciences Inc | 189,197 | 1,791,588 | -190,588 |
| Pfizer Inc | 163,675 | 849,280 | 58,267 |
| Arcus Biosciences Inc | 3,154 | 194,676 | -765,391 |
| Amphastar Pharmaceuticals Inc | 1,211 | 369,443 | 39,751 |
| PEERS TOTAL | 617,235 | 864,934 | 60,793 |
Sign in to see all peers for Cidara Therapeutics Inc .
Cidara Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 70.78 % |
| Pfizer Inc | United States 58.91 % |
| Amphastar Pharmaceuticals Inc | US 92.91 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Cidara Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Cidara Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Cidara Therapeutics Inc ranks #0 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,331, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 226,707 | 26.02 % |
| 2 | Gilead Sciences Inc | 185,928 | 21.34 % |
| 3 | Moderna Inc | 76,517 | 8.78 % |
| 4 | Argenx Se | 63,326 | 7.27 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 0 | Cidara Therapeutics Inc | 5,951 | 0.00 % |
Market cap and industry share for the rest of Cidara Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-01-06.
Cidara Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | 6.9x | 5.1x | +1.8x |
| Return on Equity | -48.32 % | industry aggregate | -60.53 % |
| Return on Invested Capital | -25.78 % | -6.17 % (avg) | -19.61 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cidara Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | -23.68 % | - |
| Operating Margin | - | - | - | -595.42 % | - | - | -49.66 % | - |
| Return on Invested Capital | -42.08 % | -45.91 % | -50.59 % | -101.43 % | -119.68 % | -138.47 % | -64.35 % | -65.37 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cidara Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,331 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Cidara Therapeutics Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Cidara Therapeutics Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Cidara Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 60.5 points below the industry aggregate.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-35.9% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Cidara Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cidara Therapeutics Inc | 5.13 | 6.07 | - |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
| Arcus Biosciences Inc | 0.93 | 3.97 | 0.19 |
| Amphastar Pharmaceuticals Inc | 1.00 | 3.21 | 0.79 |
Sign in to see all peers for Cidara Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cidara Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cidara Therapeutics Inc | Q3 2025 | - | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| Arcus Biosciences Inc | Q2 2026 | -74.4 % | - |
| Amphastar Pharmaceuticals Inc | Q2 2026 | +5.4 % | -2.2 % |
| PEERS TOTAL | +7.4 % | - |
Sign in to see all peers for Cidara Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cidara Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cidara Therapeutics Inc | Q3 2025 | - | - |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
| Arcus Biosciences Inc | Q2 2026 | - | - |
| Amphastar Pharmaceuticals Inc | Q2 2026 | +2.9 % | -33.0 % |
Sign in to see all peers for Cidara Therapeutics Inc .
Cidara Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cidara Therapeutics Inc | - | - | - |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Gilead Sciences Inc | - | - | - |
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
| Arcus Biosciences Inc | - | - | - |
| Amphastar Pharmaceuticals Inc | 4.70% | 5.33% | 10.11% |
Sign in to see all peers for Cidara Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cidara Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cidara Therapeutics Inc | - | 91.48 |
| Astrazeneca Plc | 25.38 | 4.42 |
| Gilead Sciences Inc | - | 6.21 |
| Pfizer Inc | 37.66 | 2.57 |
| Arcus Biosciences Inc | - | 26.96 |
| Amphastar Pharmaceuticals Inc | 16.21 | 1.66 |
| PEERS AVERAGE | 58.47 | 4.05 |
Sign in to see all peers for Cidara Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.